Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

11.6%

27 terminated/withdrawn out of 232 trials

Success Rate

87.4%

+0.9% vs industry average

Late-Stage Pipeline

51%

119 trials in Phase 3/4

Results Transparency

66%

123 of 187 completed trials have results

Key Signals

11 recruiting123 with results22 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 3

87(38.7%)

Phase 1

57(25.3%)

Phase 2

35(15.6%)

Phase 4

32(14.2%)

N/A

10(4.4%)

Early Phase 1

4(1.8%)

225Total

Phase 3(87)

Phase 1(57)

Phase 2(35)

Phase 4(32)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (232)

Showing 20 of 232 trials

NCT06636162Early Phase 1Recruiting

Window of Opportunity Study of DSP-0390 in Gliomas

Role: collaborator

NCT04176198Phase 1Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Role: lead

NCT07545954Phase 1Not Yet Recruiting

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

Role: collaborator

NCT06891885Phase 1Recruiting

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Role: lead

NCT05467176Active Not Recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

Role: lead

NCT07444268Phase 1Recruiting

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Role: lead

NCT07492355Phase 1Completed

TP-3654 Food Effect Study

Role: lead

NCT04988555Phase 1Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Role: lead

NCT06330805Phase 2Recruiting

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Role: collaborator

NCT06463457Phase 2Active Not Recruiting

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Role: collaborator

NCT06753331Phase 1Recruiting

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Role: lead

NCT06526819Phase 1Recruiting

SMP-3124LP in Adults With Advanced Solid Tumors

Role: lead

NCT06517940Active Not Recruiting

A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

Role: lead

NCT05879913Not ApplicableRecruiting

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Role: collaborator

NCT06650579Phase 3Recruiting

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Role: collaborator

NCT05023551Early Phase 1Active Not Recruiting

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Role: lead

NCT05605964Phase 3Completed

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Role: lead

NCT04666129Phase 1Completed

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT04328740Phase 1Completed

Phase 1 Study of Oral TP-1454

Role: lead

NCT06037668Not ApplicableCompleted

A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Role: lead